Uncover Off-Target Effects Early in Drug Discovery
To ensure efficacy and safety, confirming that compounds selectively bind to their intended targets is essential—minimizing off-target interactions that could lead to unwanted side effects.
At Pelago Bioscience, we provide comprehensive selectivity profiling through unbiased, proteome-wide protein analysis. This allows researchers to assess compound binding across individual proteins and entire biological pathways, offering insights beyond the limitations of conventional target panels. Given that many drug candidates interact with multiple physiological targets, our approach helps reveal off-target effects that traditional screening methods often miss.
Key Benefits
- Comprehensive Off-Target Detection – Unbiased, proteome-wide profiling reveals off-target interactions missed by conventional panels.
- Enhanced Drug Safety and Efficacy – Ensure selective binding to the correct targets, minimizing potential liabilities early in development.
- Flexible Service Options – Choose between fully customized profiling or a faster, standardized service in lysate.
How It Works
Our selectivity profiling process is designed to uncover off-target effects early, using a scientifically rigorous approach tailored to your needs:
- Service Selection – Choose a customized CETSA-based selectivity profiling solution or a faster, standardized lysate service.
- Proteome-Wide Screening – Comprehensive assessment of on- and off-target binding across the proteome to capture individual protein and pathway-level effects.
- Data Interpretation – In-depth analysis to identify potential liabilities, prioritize lead compounds, and support informed decision-making for further development.
Want to gain deeper insights into your compound’s selectivity?
Contact Pelago Bioscience today learn how our CETSA-powered selectivity profiling can strengthen your drug discovery process.
Contact us to learn more, to book a meeting or request a quote.